Immunic, Inc. (NASDAQ:IMUX) Short Interest Update

Immunic, Inc. (NASDAQ:IMUX) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 3,750,000 shares, a growth of 6.5% from the January 15th total of 3,520,000 shares. Based on an average trading volume of 925,600 shares, the short-interest ratio is currently 4.1 days.

Immunic Stock Performance

Immunic stock traded up $0.09 during mid-day trading on Tuesday, reaching $1.09. 1,407,690 shares of the company were exchanged, compared to its average volume of 943,350. The firm’s 50-day simple moving average is $1.03 and its two-hundred day simple moving average is $1.26. Immunic has a twelve month low of $0.92 and a twelve month high of $2.11. The firm has a market cap of $98.19 million, a PE ratio of -0.89 and a beta of 1.87.

Institutional Investors Weigh In On Immunic

Hedge funds have recently modified their holdings of the stock. State Street Corp increased its stake in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares during the period. 683 Capital Management LLC boosted its holdings in shares of Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after acquiring an additional 15,349 shares in the last quarter. Bridgeway Capital Management LLC increased its stake in shares of Immunic by 11.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after acquiring an additional 22,200 shares during the period. Focus Partners Wealth raised its holdings in Immunic by 1.1% during the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after purchasing an additional 23,610 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Immunic in the third quarter valued at about $50,000. 51.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on IMUX shares. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Monday, February 10th. HC Wainwright assumed coverage on Immunic in a report on Monday, November 25th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 target price on shares of Immunic in a report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $12.67.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.